journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Clinical Immunology

journal
https://www.readbyqxmd.com/read/29035131/ri-002-an-intravenous-immunoglobulin-containing-high-titer-neutralizing-antibody-to-rsv-and-other-respiratory-viruses-for-use-in-primary-immunodeficiency-disease-and-other-immune-compromised-populations
#1
Richard L Wasserman, Benjamin N Greener, James Mond
Novel immune globulin (IG) products (RI-002, RI-001) have been designed to provide protection against respiratory syncytial virus (RSV) mediated respiratory illness while at the same time meeting the manufacturing requirements established by FDA for antibody supplementation in immunocompromised subjects. Areas covered: This review covers the manufacture and development of both RI-001 and RI-002, including the selection of plasma donors for IG preparation with high-titers of anti-RSV antibody, in vitro, and preclinical data in the cotton rat model S...
October 16, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29034753/ataxia-telangiectasia-syndrome-moonlighting-atm
#2
Majid Zaki Dizaji, Seyed Mohammad Akrami, Hassan Abolhassani, Nima Rezaei, Asghar Aghamohammadi
Ataxia-telangiectasia (A-T) a multisystem disorder primarily characterized by cerebellar degeneration, telangiectasia, immunodeficiency, cancer susceptibility and radiation sensitivity. Identification of the gene defective in this syndrome, ataxia-telangiectasia mutated gene (ATM), and further characterization of the disorder together with a greater insight into the function of the ATM protein have expanded our knowledge about the molecular pathogenesis of this disease. Area covered: In this review, we have attempted to summarize the different roles of ATM signaling that have provided new insights into the diverse clinical phenotypes exhibited by A-T patients...
October 16, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29027827/triggering-receptor-expressed-on-myeloid-cells-in-the-pathogenesis-of-periodontitis-potential-novel-treatment-strategies
#3
Courtney P Rudick, Takanari Miyamoto, Melissa S Lang, Devendra K Agrawal
Periodontal diseases are polymicrobial inflammatory disorders of the tissue, ligament, and bone structures supporting teeth. Periodontitis (inflammation with corresponding loss of attachment) affects 40-50% of adults. Recently, members of the Triggering Receptor on Myeloid Cell (TREM) family have been studied to determine their relationship to these diseases. Areas covered: TREM-1 is a receptor expressed on the surface of PMNs, monocytes, macrophages, dendritic cells, vascular smooth muscle cells, and keratinocytes upregulated in the presence of periodontal inflammation...
October 13, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29025354/cell-bound-complement-activation-products-as-lupus-biomarkers-diagnosis-monitoring-and-stratification
#4
Joseph M Ahearn, Chau-Ching Liu, Susan Manzi
Cell-bound complement activation products (CB-CAPs) were first reported in 2004, since which time multiple laboratories have demonstrated their value as biomarkers for diagnosis, monitoring, and stratification of patients with systemic lupus erythematosus. Areas Covered: This review summarizes the highlights of these 14 years of CB-CAPs discovery and validation, concluding with a view toward their future potential for precision medicine. Expert Commentary: The practice of medicine is both art and science and each physician can be considered both artist and scientist with a variable blend of the two skill sets...
October 13, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28994348/from-pathogenesis-to-novel-therapies-in-the-treatment-of-primary-biliary-cholangitis
#5
Vincenzo Ronca, Marco Carbone, Francesca Bernuzzi, Federica Malinverno, Hani S Mousa, M Eric Gershwin, Pietro Invernizzi
Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis and fibrosis, and leading to liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapy for the treatment of PBC patients. This is effective in majority of patients; however, up to 20 percent of patients have an incomplete response to UDCA therapy and have a reduced prognosis as compared to healthy individuals. Obeticholic acid (OCA) has been recently registered as second-line therapy for patients with incomplete response to UDCA, with plans to demonstrate the long-term clinical efficacy...
October 10, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28994328/th17-treg-immunoregulation-and-implications-in-treatment-of-sulfur-mustard-gas-induced-lung-diseases
#6
Maryam Iman, Ramazan Rezaei, Sadegh Azimzadeh-Jamalkandi, Parvin Shariati, Farrah Kheradmand, Jafar Salimian
Sulfur mustard (SM) is an extremely toxic gas used in chemical warfare to cause massive lung injury and death. Victims exposed to SM gas acutely present with inhalational lung injury, but among those who survive, some develop obstructive airway diseases referred to as SM-lung syndrome. Pathophysiologically, SM-lung shares many characteristics with smoking-induced chronic obstructive pulmonary disease (COPD), including airway remodeling, goblet cell metaplasia, and obstructive ventilation defect. Some of the hallmarks of COPD pathogenesis, which include dysregulated lung inflammation, neutrophilia, recruitment of interleukin 17A (IL -17A) expressing CD4(+)T cells (Th17), and the paucity of lung regulatory T cells (Tregs), have also been described in SM-lung...
October 10, 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/29019451/autoimmunity-in-a-cohort-of-471-patients-with-primary-antibody-deficiencies
#7
Gholamreza Azizi, Marzieh Tavakol, Hosein Rafiemanesh, Fatemeh Kiaee, Reza Yazdani, Amin Heydari, Kosar Abouhamzeh, Pardis Anvari, Sara Mohammadikhajehdehi, Laleh Sharifia, Yasser Bagheri, Hamed Mohammadi, Hassan Abolhassani, Asghar Aghamohammadi
OBJECTIVES: The aim of this study was to evaluate the frequency of autoimmunity in primary antibody deficiency (PAD). METHODS: A total of 471 patients with PADs enrolled in this retrospective cohort study. For all patients' demographic information, clinical records and laboratory data were collected to investigate autoimmune complications. RESULTS: Autoimmune disorders as the first presentation of immunodeficiency were recorded in 11 patients (2...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28972799/immune-function-a-missing-link-in-the-gender-disparity-in-preterm-neonatal-outcomes
#8
David N O'Driscoll, Catherine M Greene, Eleanor J Molloy
In neonatology, males exhibit a more severe disease course and poorer prognosis in many pathological states when compared to females. Perinatal brain injury, respiratory morbidity, and sepsis, among other complications, preferentially affect males. Preterm neonates (born <37 weeks gestation) display a particularly marked sexual disparity in pathology, especially at the borders of viability. The sex biases in preterm neonatal outcomes and underlying multifactorial mechanisms have been incompletely explored...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28965431/chemokines-as-adjuvants-for-immunotherapy-implications-for-immune-activation-with-ccl3
#9
Teilo H Schaller, Kristen A Batich, Carter M Suryadevara, Rupen Desai, John H Sampson
Immunotherapy embodies any approach that manipulates the immune system for therapeutic benefit. In this regard, various clinical trials have employed direct vaccination with patient-specific dendritic cells or adoptive T cell therapy to target highly aggressive tumors. Both modalities have demonstrated great specificity, an advantage that is unmatched by other treatment strategies. However, their full potential has yet to be realized. Areas covered: In this review, we provide an overview of chemokines in pathogen and anti-tumor immune responses and discuss further improving immunotherapies by arming particular chemokine axes...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28918671/long-term-outcomes-of-severe-combined-immunodeficiency-therapy-implications
#10
Jennifer Heimall, Morton J Cowan
Newborn screening has led to a better understanding of the prevalence of Severe Combined Immunodeficiency (SCID) overall and in terms of specific genotypes. Survival has improved following hematopoietic stem cell transplantation (HCT) with the best outcomes seen following use of a matched sibling donor. However, questions remain regarding the optimal alternative donor source, appropriate use of conditioning and the impact of these decisions on immune reconstitution and other late morbidities. Areas covered: The currently available literature reporting late effects after HCT for SCID and use of alternative therapies including enzyme replacement, alternative donors and gene therapy are reviewed...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28918659/ureaplasma-associated-prenatal-perinatal-and-neonatal-morbidities
#11
Christine Silwedel, Christian P Speer, Kirsten Glaser
Ureaplasma species (spp.) have been acknowledged as major causative pathogens in chorioamnionitis and prematurity, but may also contribute to key morbidities in preterm infants. Several epidemiological and experimental data indicate an association of neonatal Ureaplasma colonization and/or infection with bronchopulmonary dysplasia. Furthermore, a potential causal relation with other inflammation-induced morbidities, such as intraventricular hemorrhage, white matter injury, necrotizing enterocolitis, and retinopathy of prematurity, has been debated...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28893093/practical-approach-to-the-treatment-of-nsaid-hypersensitivity
#12
Natalia Blanca-Lopez, Diana Perez-Alzate, Gabriela Canto, Miguel Blanca
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently involved in drug hypersensitivity reactions (DHR). NSAIDs are prescribed for different processes and some NSAIDs can be obtained over the counter. Areas covered: We analyse the practical approaches for managing and treating NSAID-DHR considering the five major groups of entities recognised, divided into two categories: those responding to strong COX-1 inhibitors and possibly weak COX-1 or selective COX-2 inhibitors named cross-intolerant (CI), and those induced by a single drug or drug group with good tolerance to strong COX-1 inhibitors, known as allergic reactions (SR)...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28870100/biologic-drugs-in-adult-onset-still-s-disease-a-systematic-review-and-meta-analysis-of-observational-studies
#13
Piero Ruscitti, Francesco Ursini, Paola Cipriani, Giovambattista De Sarro, Roberto Giacomelli
BACKGROUND: Biological drugs, mainly interleukin (IL)-1 and IL-6 antagonists, but also tumor necrosis factor (TNF) inhibitors, have been used in the treatment of adult onset Still's disease patients (AOSD). METHODS: We summarised the available evidence for the effectiveness of biologic drugs in AOSD. A systematic review of the literature was performed in order to identify all the available data concerning the effectiveness of biologic drugs in AOSD. The proportion of patients achieving complete remission or any clinical response was calculated...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28837367/advances-in-immunopathogenesis-of-macrophage-activation-syndrome-during-rheumatic-inflammatory-diseases-toward-new-therapeutic-targets
#14
Piero Ruscitti, Paola Cipriani, Paola Di Benedetto, Vasiliky Liakouli, Francesco Carubbi, Onorina Berardicurti, Francesco Ciccia, Giuliana Guggino, Giovanni Triolo, Roberto Giacomelli
Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies...
November 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28847197/subcutaneous-and-intravenous-belimumab-in-the-treatment-of-systemic-lupus-erythematosus-a-review-of-data-on-subcutaneous-and-intravenous-administration
#15
Y J Poh, B Baptista, David P D'Cruz
Loss of B cell tolerance is a hallmark feature of the pathogenesis of Systemic Lupus Erythematosus (SLE). Recent advances in B cell therapy have focused on targeted therapy aimed at inhibiting B cell activation and reducing B cell survival. Belimumab, a human monoclonal antibody against B cell activating factor (BAFF) was licensed in 2011 for the treatment of SLE. Areas covered: We review the data on the intravenous and subcutaneous formulations of belimumab in the management of patients with SLE. BLISS-52 and BLISS-76 demonstrated the efficacy of intravenous belimumab (10mg/kg) as an add-on therapy in SLE patients with active disease...
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28829205/potential-applications-of-bruton-s-tyrosine-kinase-inhibitors-for-the-prevention-of-allergic-reactions
#16
Melanie C Dispenza, Jennifer A Regan, Bruce S Bochner
No abstract text is available yet for this article.
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28812393/innate-lymphoid-cells-the-role-in-respiratory-infections-and-lung-tissue-damage
#17
Anna Głobińska, Marek L Kowalski
Innate lymphoid cells (ILCs) represent a diverse family of cells of the innate immune system, which play an important role in regulation of tissue homeostasis, immunity and inflammation. Emerging evidence has highlighted the importance of ILCs in both protective immunity to respiratory infections and their pathological roles in the lungs. Therefore, the aim of this review is to summarize the current knowledge, interpret and integrate it into broader perspective, enabling greater insight into the role of ILCs in respiratory diseases...
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28800401/lupus-nephritis-and-b-cell-targeting-therapy
#18
Matthias Cassia, Federico Alberici, Maurizio Gallieni, David Jayne
Lupus Nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE) with a significant prognostic impact. Over a prolonged course, an exhaustion of treatment alternatives may occur and further therapeutic options are needed. B cells play a pivotal role in disease pathogenesis and represent an attractive therapeutic target. Areas covered: This review provides an update regarding targeting B cells in LN. The rational for this approach, as well as currently available and future targets are discussed...
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28795649/immunotherapy-of-cancers-comes-of-age
#19
Hila Yousefi, Jianda Yuan, Mahsa Keshavarz-Fathi, Joseph F Murphy, Nima Rezaei
Cancer immunotherapy has evolved and is aimed at generating the efficacious therapeutic modality to enhance the specificity and power of the immune system to combat tumors. Areas covered: Current efforts in cancer immunotherapy fall into three main approaches. One approach is through the blockade of immune checkpoints, another approach is through adoptive cellular therapy, and the last approach is through vaccination. The goal of this review is to summarize the current understanding and status of cancer immunotherapy in these three categories...
October 2017: Expert Review of Clinical Immunology
https://www.readbyqxmd.com/read/28749245/advances-in-our-understanding-of-immunization-and-vaccines-for-patients-with-systemic-lupus-erythematosus
#20
Nicola Luigi Bragazzi, Abdulla Watad, Kassem Sharif, Mohammad Adawi, Gali Aljadeff, Howard Amital, Yehuda Shoenfeld
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease. In SLE, immune system dysfunction is postulated to result by virtue of the disease itself as well as by the impact of treatment modalities employed. A myriad of immune dysregulations occur including complement system dysfunction among others. Infectious agents are known to complicate the disease course in close to 25-45% of SLE patients. Areas covered: In this review a discussion of the immunogenicity and safety of viral and bacterial vaccinations in SLE was performed...
October 2017: Expert Review of Clinical Immunology
journal
journal
41324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"